United States: Jury Finds For Drug Manufacturers In First Post-Actavis "Reverse Payment" Trial

Last Updated: December 15 2014
Article by Kevin D. McDonald, Jonathan Berman and Aimee DeFilippo
Most Read Contributor in United States, September 2019

In the first "reverse payment" trial since the U.S. Supreme Court's Actavis decision held that "reverse payment" settlements potentially could be found anticompetitive under a rule of reason analysis, a federal jury in Massachusetts has returned a verdict in favor of the pharmaceutical companies, concluding the settlement did not harm competition. The December 5 decision came in In Re Nexium (Esomeprazole) Antitrust Litigation.


Direct and indirect purchasers of the drug Nexium sued AstraZeneca, the manufacturer of Nexium, and three manufacturers (Ranbaxy Inc., Teva Pharmaceuticals, and Dr. Reddy's Laboratories) that had announced intentions to sell generic versions of Nexium. The plaintiffs alleged that these manufacturers entered into unlawful "reverse payment" agreements, allegedly in violation of the Sherman Act, when they made settlement agreements resolving Hatch-Waxman patent litigation.

In a "reverse payment" settlement, a branded-drug manufacturer settles a challenge to its patent by providing compensation to a generic challenger. In exchange, a generic manufacturer typically agrees to drop its patent challenge and enter the market as a licensee at some later time before the patent expires. For years, the majority of appellate courts had held that, since all Hatch-Waxman settlements convey consideration to the generic challenger, those settlements did not reduce lawful competition as long as they foreclosed only potentially infringing competition, that is, as long as they were within the scope of the patent. In Actavis, the Supreme Court rejected the scope of the patent test, holding that such a settlement with an "unexplained large reverse payment" may violate the antitrust laws under a "rule of reason" balancing test. The Court provided little guidance (some would say none) as to how that rule of reason analysis was to be carried out.

In Nexium, the 2008 settlement between Ranbaxy and AstraZeneca provided that Ranbaxy would become the exclusive authorized generic distributor for the first six months after the expiry of certain Nexium patents in May 2014. Plaintiffs alleged that this "no AG" (no authorized generic) clause was a pay-off for delay, allegedly worth hundreds of millions of dollars. Ranbaxy and AstraZeneca also entered into manufacturing and distribution agreements, which plaintiffs alleged also constituted part of the alleged unlawful payment to Ranbaxy.

AstraZeneca's settlements with Teva and Dr. Reddy's granted licenses for the respective companies to sell generic Nexium starting in May 2014, assuming their products received FDA approval. Plaintiffs alleged that Teva and Dr. Reddy's also received payments through the simultaneous settlement of unrelated patent litigation. When resolving summary judgment motions, the Court determined that Dr. Reddy's had not received a reverse payment. The Court deemed triable the allegation that Teva received a payment, and those issues dominated the early portions of the trial.

Dr. Reddy's settled the antitrust claims immediately before trial began through settlements that did not require the payment of any money to the plaintiff classes (a "zero dollar" settlement). Dr. Reddy's agreed to let plaintiffs call some of its personnel as witnesses, but the plaintiffs never did so. Teva settled during trial, after conspiracy claims linking the Teva and Ranbaxy settlements were dismissed on a directed verdict. The terms of the Teva settlement have not yet been disclosed.

At trial, the plaintiffs argued that AstraZeneca's agreements with Ranbaxy, consistent with the Supreme Court's Actavis decision, contained an "unexplained large reverse payment" designed to delay generic entry. Plaintiffs asserted that, but for the settlement agreement, a cheaper, generic Nexium would have entered the market sooner than would occur pursuant to the settlement agreement. Plaintiffs also claimed that they were overcharged for Nexium as a result of the settlement between AstraZeneca and Ranbaxy. Since Ranbaxy has not yet received FDA approval to market its generic Nexium product, and since the Court had previously ruled that there was insufficient evidence that Ranbaxy could have obtained FDA approval at some earlier date, plaintiffs' causation argument was complicated. Plaintiffs alleged that absent the alleged payment, AstraZeneca would have licensed Ranbaxy (and Teva) to enter at an earlier date; that Teva would have paid Ranbaxy to forfeit the 180-day exclusivity that the Hatch-Waxman Act awards to the first generic to file for FDA approval, and that Teva (which also does not have FDA approval for its product) would have accelerated its efforts to obtain FDA approval.

Defendants responded that the plaintiffs' case rested entirely on speculation. One point of emphasis was that no company could have produced a generic Nexium product sooner because no generic manufacturer has received even tentative FDA approval. Thus, according to the defendants, the settlement did not cause any delay in the generics' launches of their generic Nexium products.


The jury found that AstraZeneca possessed the necessary market power over Nexium and that the settlement contained a "large and unjustified" payment" as required by the Supreme Court in Actavis. The jury also found that the settlement was "unreasonably anticompetitive" and that its anticompetitive nature was not outweighed by any procompetitive justifications. However, the jury ultimately concluded that regardless of the "anticompetitive" settlement, AstraZeneca would not have granted Ranbaxy an earlier entry date than the one it did. Accordingly, the settlement could not have harmed the drug's purchasers.


While courts are still wrangling with how to interpret Actavis – and this case indicates that the wrangling is far from over – it offers some initial lessons for companies who have settled Hatch-Waxman cases or contemplate doing so. First, jurors are able to parse out the unique issues within "reverse payment" cases. Here, jurors concluded that the payment was "large and unjustified" and that the settlement was "unreasonably anticompetitive." Nonetheless the jury decided for defendants on a critical causation issue. Second, this case also demonstrates that causation will continue to be a central issue in "reverse payment" cases. Here, the antitrust plaintiffs faced the uncomfortable fact that the May 2014 license date for all the generics came and went without generic entry or even FDA approval of a generic Nexium. Nexium thus underscores that plaintiffs in all "reverse payment" cases bear the burden of proving not just a payment, but also what would have happened in the absence of a payment, and that burden can be quite heavy. Here, even though the jury did find the existence of a payment from the brand to the first-to-file generic, the jury was not swayed by the assertions of plaintiffs and their experts that any payment "must have" caused a delay.

Nexium is just the first of many post-Actavis "reverse payment" cases making their way through the courts. Without the unique facts at issue in the Nexium case, the outcome of those other cases should tell us much more about how courts and juries view patent settlements in the post-Actavis world.

Jones Day represented Dr. Reddy's Laboratories in this case. 

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Similar Articles
Relevancy Powered by MondaqAI
In association with
Related Topics
Similar Articles
Relevancy Powered by MondaqAI
Related Articles
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Mondaq Free Registration
Gain access to Mondaq global archive of over 375,000 articles covering 200 countries with a personalised News Alert and automatic login on this device.
Mondaq News Alert (some suggested topics and region)
Select Topics
Registration (please scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.


The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.


Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions